Alden Klarer, Ph.D.
Affiliations: | 2013 | University of Louisville, Louisville, KY, United States |
Area:
Biochemistry, Molecular BiologyGoogle:
"Alden Klarer"Mean distance: (not calculated yet)
Parents
Sign in to add mentorSucheta Telang | grad student | 2013 | University of Louisville | |
(6-Phosphofructo-2-kinase inhibition induces autophagy as a survival mechanism.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Clem BF, O'Neal J, Klarer AC, et al. (2016) Clinical development of cancer therapeutics that target metabolism. Qjm : Monthly Journal of the Association of Physicians. 109: 367-72 |
Chesney J, Clark J, Klarer AC, et al. (2014) Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget. 5: 6670-86 |
Yalcin A, Clem BF, Imbert-Fernandez Y, et al. (2014) 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death & Disease. 5: e1337 |
Klarer AC, O'Neal J, Imbert-Fernandez Y, et al. (2014) Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer & Metabolism. 2: 2 |
Clem BF, O'Neal J, Tapolsky G, et al. (2013) Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Molecular Cancer Therapeutics. 12: 1461-70 |
Telang S, Nelson KK, Siow DL, et al. (2012) Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Molecular Cancer. 11: 60 |
Telang S, Clem BF, Klarer AC, et al. (2012) Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. Journal of Translational Medicine. 10: 95 |
Chesney J, Rasku MA, Klarer AC, et al. (2011) Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2507 |
Telang S, Rasku MA, Clem AL, et al. (2011) Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. Bmc Cancer. 11: 515 |